Peripheral human CD8(+)CD28(+)T lymphocytes give rise to CD28(-)progeny, but IL-4 prevents loss of CD28 expression.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Peripheral human CD8(+)CD28(+)T lymphocytes give rise to CD28(-)progeny, but IL-4 prevents loss of CD28 expression.

Int Immunol. 1999 Aug;11(8):1327-36. Unique Identifier : AIDSLINE MED/99352263
Labalette M; Leteurtre E; Thumerelle C; Grutzmacher C; Tourvieille B; Dessaint JP; Service d'Immunologie, EA 2686, Centre Hospitalier et; Universitaire de Lille, 59045 Lille, France.

Abstract: At birth, virtually all peripheral CD8(+) T cells express the CD28 co-stimulatory molecule, but healthy human adults accumulate CD28(-)CD8(+) T cells that often express the CD57 marker. While these CD28(-) subpopulations are known to exert effector-type functions, the generation, maintenance and regulation of CD28(-) (CD57(+) or CD57(-)) subpopulations remain unresolved. Here, we compared the differentiation of CD8(+)CD28(bright)CD57(-) T cells purified from healthy adults or neonates and propagated in IL-2, alone or with IL-4. With IL-2 alone, CD8(+)CD28(bright)CD57(-) T cell cultures yielded a prevailing CD28(-) subpopulation. The few persisting CD28(dim) and the major CD28(-) cells were characterized by similar telomere shortening at the plateau phase of cell growth. Cultures from adults donors generated four final CD8(+) phenotypes: a major CD28(-)CD57(+), and three minor CD28(-)CD57(-), CD28(dim)CD57(-) and CD28(dim)CD57(dim). These four end-stage CD8(+) subpopulations displayed a fairly similar representation of TCR V(beta) genes. In cultures initiated with umbilical cord blood, virtually all the original CD8(+)CD28(bright) T cells lost expression of CD28, but none acquired CD57 with IL-2 alone. IL-4 impacted on the differentiation pathways of the CD8(+)CD28(bright)CD57(-) T cells: the addition of IL-4 led both the neonatal and the adult lymphocytes to keep their expression of CD28. Thus, CD8(+)CD28(bright)CD57(-) T cells can give rise to four end-stage subpopulations, the balance of which is controlled by both the cytokine environment, IL-4 in particular, and the proportions of naive and memory CD8(+)CD28(+) T cells.

Keywords: JOURNAL ARTICLE Adult Animal Antigens, CD28/GENETICS/*METABOLISM Antigens, CD57/METABOLISM Cell Differentiation Cells, Cultured Cytokines/BIOSYNTHESIS CD8-Positive T-Lymphocytes/*CYTOLOGY/IMMUNOLOGY Female Fetal Blood/IMMUNOLOGY Genes, T-Cell Receptor beta Human Immunologic Memory Interleukin-2/IMMUNOLOGY/METABOLISM Interleukin-4/*IMMUNOLOGY/METABOLISM Leukocytes, Mononuclear/*CYTOLOGY/IMMUNOLOGY Lymphocyte Transformation Mice Middle Age Pregnancy Support, Non-U.S. Gov't T-Lymphocyte Subsets/*CYTOLOGY/IMMUNOLOGY Telomere/GENETICS
991230
A99C1073

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .